$143.37
Value $354B
MRK and OMER stock compared: price, dividend, valuation and results, from SEC filings.
$143.37
Value $354B
$13.92
Value $1.0B
Merck & Company (MRK) has a market value of $354B and Omeros (OMER) $1.0B. Over the last year, with dividends, MRK moved +58.8% and OMER +76.9%. The P/E is 144.5 for MRK and 10.2 for OMER. Dividend yield: MRK 2.37%, OMER none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
MRK$354B
OMER$1.0B
MRK is 354 times OMER
Revenue, 12 months
MRK$67.4B
OMER–
Net income, 12 months
MRK$2.5B
OMER$98M
MRK is 25 times OMER
Operating margin
MRK–
OMER–
ROIC
MRK3.9%
OMER–
P/E
MRK144.5
OMER10.2
MRK is 14 times OMER
Dividend yield
MRK2.4%
OMER0.0%
2.4 points apart
5-year return
MRK+98.6%
OMER+68.9%
29.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
MRK+98.6%
OMER+68.9%
| Period | MRKWith dividends | OMERWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +58.8%Price +54.3% | +76.9%Price +76.9% |
| 3 years since November 17, 2023 | +54.4%+15.6% a yearPrice +40.9% | +748.8%+104.0% a yearPrice +748.8% |
| 5 years since November 16, 2021 | +98.6%+14.7% a yearPrice +70.5% | +68.9%+11.1% a yearPrice +68.9% |
| 10 years since November 17, 2016 | +225.1%+12.5% a yearPrice +139.6% | +5.1%+0.5% a yearPrice +5.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
MRKMerck & CompanyOMEROmeros
| Price | $143.37 | $13.92 |
|---|---|---|
| Market value | $354B | $1.0B |
| Enterprise value (EV) | $399B | – |
| P/E | 144.5 | 10.2 |
| P/E, 5-year median | 14.8 | – |
| P/B | 7.9 | – |
| EV/EBIT | 83.7 | – |
| Free cash flow yield | 4.2% | – |
| Revenue, 12 months | $67.4B | – |
|---|---|---|
| Net income, 12 months | $2.5B | $98M |
| Free cash flow, 12 months | $14.7B | -$37M |
| Earnings per share, 12 months | $0.98 | $1.37 |
| Revenue growth, year on year | 1.3% | -34.0% |
| Revenue growth a year, past | +9.4%over 5 years | +15.4%over 4 years |
| EPS growth a year, past | +21.2%over 5 years | – |
| Gross margin | 71.8% | – |
|---|---|---|
| Operating margin | – | – |
| Net margin | 3.6% | – |
| ROIC | 3.9% | – |
| ROE | 5.2% | – |
| Cash | $9.7B | $95M |
|---|---|---|
| Total debt | $53.8B | – |
| Net debt / EBITDA | 5.7 | – |
| Interest cover | 2.4× | -4.3× |
| Dividend yield | 2.4% | – |
|---|---|---|
| Dividend per share, 12 months | $3.40 | – |
| Dividend growth a year, past | +5.8%over 5 years | – |
| Buyback yield | 1.4% | – |
| Shareholder yield | 3.8% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($354B) is about 353.7 times Omeros ($1.0B), at today's prices.
Since November 17, 2016, MRK's price moved +139.6% and OMER's +5.1%. With dividends: MRK +225.1% (+12.5% a year), OMER +5.1% (+0.5% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.37% for Merck & Company and none for Omeros. Over the last twelve months they paid $3.40 and – per share.
At today's price, the P/E is 144.5 for MRK and 10.2 for OMER. It is the share price over the last twelve months' earnings per share.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.